Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.53 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | QPCT | Q16769 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737402 | 0.82 | MAPT (0.63) | MAOBMAOAABCB1 | |
| SCHEMBL739211 | 0.78 | KMT2A (0.61) | ACHEBCHEGAASIMAOB | |
| SCHEMBL971282 | 0.76 | ABCB1 (0.61) | SIMAOBMAOAABCB1 | |
| SCHEMBL17185543 | 0.75 | ABCB1 (0.69) | ACHEBCHEMGAMGAASI | |
| SCHEMBL19129536 | 0.74 | ACHE (0.63) | ACHEBCHEMGAMGAASI | |
| SCHEMBL21226275 | 0.69 | CYP1A1 (0.72) | ACHEMGAMGAASIMGAM2 | |
| Pisonin E SCHEMBL30879929 | 0.68 | PTGS1 (0.56) | GAA | |
| SCHEMBL4152555 | 0.66 | ABCB1 (0.93) | ACHEBCHEGAAMAOBMAOA | |
| SCHEMBL7082749 | 0.66 | CYP2D6 (0.73) | ACHEBCHEABCB1 | |
| SCHEMBL13661091 | 0.65 | MAOB (0.65) | MAOBMAOAQPCTABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138165-B2 | Chromones and chromone derivatives and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-1556031-A4 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | JENKEN BIOSCIENCES INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20060142211-A1 | Chromones and chromone derivatives and uses thereof | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2006-06-29 | — | — | US | disclosed |
| EP-1556031-A2 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | Jenken Bioscience, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037193-A2 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | JENKEN BIOSCIENCES, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142211-A1 | Chromones and chromone derivatives and uses thereof | PROC, HMGB1, PYCARD | ACHE 1386/4885BCHE 1414/4885MGAM 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.